The treatment of migraine patients with triptans – is there a need for further Rx-to-OTC switches?

N.N

doi:10.1055/a-0836-2852

CareLit Fachartikel

The treatment of migraine patients with triptans – is there a need for further Rx-to-OTC switches?

N.N. · Gesundheitsökonomie & Qualitätsmanagement · 2019 · Heft 1 · S. 15 bis 23

Dokument

251735

CareLit-ID

Jahr

2019

Publikation

PDF

nein

Metadaten

DOI

ja

zitierfähig

Bibliografische Angaben

Zeitschrift

Gesundheitsökonomie & Qualitätsmanagement

Autor:innen

N.N.

Ausgabe

Heft 1 / 2019

Jahrgang 19

Seiten

15 bis 23

Erschienen: 2019-01-15 03:06:59

ISSN

1432-2625

DOI

10.1055/a-0836-2852

Zusammenfassung

Abstract Objective The disease migraine affects a large share of the German population and is linked to a high economic potential in terms of direct and indirect sickness costs. Triptans are the recommended treatment in the case of an acute migraine attack. Both, the disease and its appropriate treatment are of interest in the context of self-medication and Rx-to-OTC switch efforts. Therefore, a survey was carried out with the intention to collect data among migraine patients regarding the use of analgesics in general and of triptans specifically. This data can be the basis for further health economic considerat…